Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only
Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.
This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
Close date: 31 December 2021
Register here: https://bit.ly/2YNFpaE